“My Fulbright project aims to increase the efficacy of the drug testing pipeline by generating more predictive and reproducible drug screening models. We will fabricate microfluidic cell culture devices that accurately mimic the human body to forecast patient responses, expediting drug discovery and decreasing off-target effects for clinical trial participants”, says Laura Milton, CBT PhD Candidate.
Laura is a biomedical engineering PhD candidate who generates micro-scale drug testing platforms. She graduated from the University of Queensland as Valedictorian of the School of Biomedical Sciences, then moved to biomedical engineering to address drug testing pipeline inefficacies. Laura now combines microfluidic cell culture devices with bespoke biomaterials and cell constructs, using them to develop predictive and reproducible drug screening models which forecast patient responses.
As a Fulbright Scholar, Laura will work with leading microfluidics researchers at the University of Washington to develop microfluidic drug screening platforms for a variety of disorders.
Read about all the Australian Fulbright Scholars 2024 here.